Eupraxia Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Eupraxia Pharmaceuticals's estimated annual revenue is currently $3.5M per year.
- Eupraxia Pharmaceuticals's estimated revenue per employee is $89,744
- Eupraxia Pharmaceuticals's total funding is $10M.
Employee Data
- Eupraxia Pharmaceuticals has 39 Employees.
- Eupraxia Pharmaceuticals grew their employee count by 15% last year.
Eupraxia Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President & CFO | Reveal Email/Phone |
2 | VP, Translational Science | Reveal Email/Phone |
3 | SVP Operations | Reveal Email/Phone |
4 | VP, Finance | Reveal Email/Phone |
5 | VP, Finance | Reveal Email/Phone |
6 | VP, Program Management, Regulatory and Quality Affairs | Reveal Email/Phone |
7 | VP, Pharmacometrics and Data Analytics | Reveal Email/Phone |
8 | VP, Clinical Development | Reveal Email/Phone |
9 | Senior Director Chemistry, Manufacturing and Controls | Reveal Email/Phone |
10 | Chief Scientific Officer | Reveal Email/Phone |
Eupraxia Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $3.1M | 40 | 18% | $40M | N/A |
#2 | $0.2M | 2 | 0% | N/A | N/A |
#3 | $1.3M | 17 | -15% | N/A | N/A |
#4 | $2.6M | 17 | 6% | N/A | N/A |
#5 | $12.9M | 83 | 5% | N/A | N/A |
#6 | $1.9M | 24 | 4% | $89.5M | N/A |
#7 | $2.8M | 18 | 6% | N/A | N/A |
#8 | $40.3M | 260 | 21% | N/A | N/A |
#9 | $0.9M | 6 | 0% | N/A | N/A |
#10 | $0.6M | 4 | -20% | N/A | N/A |
What Is Eupraxia Pharmaceuticals?
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia's product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia’s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.
keywords:N/A
$10M
Total Funding
39
Number of Employees
$3.5M
Revenue (est)
15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Eupraxia Pharmaceuticals News
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF Get Rating) had its price objective dropped by stock analysts at Canaccord Genuity Group from...
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently...
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently...
Other Companies in Victoria
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.2M | 40 | 11% | $10B |
#2 | $8.2M | 41 | -2% | $2.3B |
#3 | $7.5M | 41 | -7% | N/A |
#4 | $8.9M | 41 | 46% | N/A |
#5 | $7.1M | 42 | 5% | N/A |